Author: ["Reiko Hanada","Hitoshi Teranishi","James Todd Pearson","Mamoru Kurokawa","Hiroshi Hosoda","Nobuhiro Fukushima","Yoshihiko Fukue","Ryota Serino","Hiroaki Fujihara","Yoichi Ueta","Masahito Ikawa","Masaru Okabe","Noboru Murakami","Mikiyasu Shirai","Hironobu Yoshimatsu","Kenji Kangawa","Masayasu Kojima"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Neuromedin U (NMU) is a hypothalamic neuropeptide that regulates body weight and composition. Here we show that mice lacking the gene encoding NMU (Nmu−/− mice) develop obesity. Nmu−/− mice showed increased body weight and adiposity, hyperphagia, and decreased locomotor activity and energy expenditure. Obese Nmu−/− mice developed hyperleptinemia, hyperinsulinemia, late-onset hyperglycemia and hyperlipidemia. Notably, however, treatment with exogenous leptin was effective in reducing body weight in obese Nmu−/− mice. In addition, central leptin administration did not affect NMU gene expression in the hypothalamus of rats. These results indicate that NMU plays an important role in the regulation of feeding behavior and energy metabolism independent of the leptin signaling pathway. These characteristic functions of NMU may provide new insight for understanding the pathophysiological basis of obesity.Cite this article
Hanada, R., Teranishi, H., Pearson, J. et al. Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway. Nat Med 10, 1067–1073 (2004). https://doi.org/10.1038/nm1106 